Great post Hieupham! This points out a real tragedy which is also occurring in the USA. By pricing the medication so high initially, Gilead caused the insurance companies here to institute very restrictive access guidelines. Only patients at F3+ currently qualify for treatment under most plans. The tragedy is that as prices are being reduced, the insurance companies are not changing their treatment guidelines. So prices will have to fall still further until more patients are treated. It's even possible that even with further reductions, treatment access will be limited.
It's really up to the individual in USA to save themselves and buy generic meds here through FixHepC.
Gt 1a, F0, VL 6.5 million, AST 59, ALT 62
Started Twinvir 1/15/16
6 wk. labs VL UND, AST 27, ALT 20
EOT labs VL UND, AST 23, ALT 19
SVR 16, VL UND, AST 28, ALT 17
SVR 24 , VL UND, 10/8/16
SVR 125, VL UND, 9/22/18
SVR 230, VL UND, 10/3/20